TABLE 2.
Priming with DC protects against peripheral infection and virus-induced immunopathology
| Immunization (no. of bmDC)a | Log10 PFU of Vacc-G2/ovaryb | No. of mice protected against intracerebral LCMV infection/no. testedc |
|---|---|---|
| 105 H8-bmDC | <0.7 | 5/5 |
| 104 H8-bmDC | <0.7 | 1/5 |
| 103 H8-bmDC | 4.1 ± 3.5 | 0/5 |
| None | 6.5 ± 1.05 | 0/5 |
| 105 B6-bmDC | 6.3 ± 0.7 | 0/3 |
C57BL/6 mice were immunized i.v. with H8-bmDC or unlabeled B6-bmDC or left untreated.
Mice were challenged with 2 × 106 PFU of Vacc-G2 intraperitoneally. Five days later, vaccinia virus titers were determined on BSC40 cells (three to five mice per group) and are reported as mean ± standard deviation. Statistical analysis of the data with an unpaired t test revealed two-tailed significance at P < 0.05 among the groups. Data from one of two experiments are shown.
Mice were challenged with 30 PFU of LCMV strain WE intracerebrally and observed twice daily for the occurrence of convulsive lymphocytic choriomeningitis. Statistical analysis of the data with an unpaired t test revealed two-tailed significance of P < 0.05 among the groups.